ATRA Atara Biotherapeutics, Inc.

17.55
+2  (10%)
Previous Close 15.95
Open 16.10
Price To book 1.82
Market Cap 510.51M
Shares 29,089,000
Volume 526,048
Short Ratio 12.82
Av. Daily Volume 276,931

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial planned for 2017. Trial design confirmed.
ATA 129
Epstein-Barr virus (EBV-PTLD) after solid organ transplant (SOT)
Phase 3 trial planned for 2017. Trial design confirmed.
ATA 129 - MATCH
Epstein-Barr virus (EBV-PTLD) after after hematopoietic cell transplant (HCT)
Phase 1/2 trial to be initiated 2018.
ATA129 and KEYTRUDA
Nasopharyngeal carcinoma (NPC)
Phase 2 endpoint not met December 2015
PINTA 745
Protein-energy wasting
Phase 2 data released at ASH 2015. Expects to meet with FDA during 4Q 2016 to discuss further development
CMV-CTL
Refractory CMV Chorioretinitis or Meningoencephalitis